Developing a cancer drug is one of the most expensive, slow, and failure-prone processes in modern science. PharosAI is trying to change that – by building multimodal, AI-ready datasets from donated cancer tissue samples and making them available to researchers, biotech companies, and clinicians.
In this episode, Technical Director Adrian La Porta speaks with PharosAI's Dr Lucie Burgess (COO) and Dr Emma Colliver (Research Fellow) about what it takes to curate cancer data at scale, why federated learning matters for patient privacy, where AI is already transforming diagnostics, and what synthetic patients could mean for clinical trials.
Whether you work in life sciences, pharma manufacturing, digital health, or clinical data governance, understanding how AI is reshaping the drug discovery pipeline has direct implications for how and when new facilities will need to be built. This one is worth your time.
Topics covered: 00:00 Introduction 00:01 What is PharosAI? 00:06 Why AI can fundamentally change cancer care 00:08 The venture behind the mission 00:12 Lowering the barrier for UK biotech 00:16 Are we at an inflection point? 00:20 AI in diagnostics – what's already working 00:24 Misconceptions about AI in biotech 00:30 Data – acquiring, cleaning, and structuring 00:34 Patient privacy, consent, and NHS data 00:37 What cancer care could look like in 10 years 00:40 Why this work matters personally
Podden och tillhörande omslagsbild på den här sidan tillhör
Bryden Wood. Innehållet i podden är skapat av Bryden Wood och inte av,
eller tillsammans med, Poddtoppen.
